STVN

Stevanato Group SpA

Add to Watchlist

Advanced Chart

21.000

-0.580(-2.690%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

21.695

Open

21.540

VWAP

21.13

Vol

338.94K

Mkt Cap

5.73B

Low

20.785

Amount

7.16M

EV/EBITDA(TTM)

22.28

Total Shares

272.77M

6.23B

EV/OCF(TTM)

37.03

P/S(TTM)

5.12

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

297.53M

+7.06%

0.151

+15.96%

273.06M

+5.18%

0.123

+24.94%

247.48M

+4.87%

0.099

+14.85%

Estimates Revision

The market is revising Downward the revenue expectations for Stevanato Group S.p.A. (STVN) for FY2025, with the revenue forecasts being adjusted by -0.24% over the past three months. During the same period, the stock price has changed by -4.24%.

Revenue Estimates for FY2025

Revise Downward

-0.24%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.89%

In Past 3 Month

Stock Price

Go Down

-4.24%

In Past 3 Month

5 Analyst Rating

19.67% Upside

Wall Street analysts forecast STVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STVN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

19.67% Upside

Current: 21.000

Low

23.00

Averages

25.13

High

28.00

19.67% Upside

Current: 21.000

Low

23.00

Averages

25.13

High

28.00

UBS

John Sourbeer

Hold

Maintains

$24 → $24

2025-03-07

Reason

UBS

John Sourbeer

Price Target

$24 → $24

2025-03-07

Maintains

Hold

Reason

Wolfe Research

Doug Schenkel

Buy

Initiates

$28

2024-12-13

Reason

Wolfe Research

Doug Schenkel

Price Target

$28

2024-12-13

Initiates

Buy

Reason

Wolfe Research analyst Doug Schenkel initiated coverage of Stevanato Group with an Outperform rating and $28 price target.

B of A Securities

Derik De Bruin

Strong Buy

Maintains

$24 → $26

2024-12-13

Reason

B of A Securities

Derik De Bruin

Price Target

$24 → $26

2024-12-13

Maintains

Strong Buy

Reason

BofA raised the firm's price target on Stevanato Group to $26 from $24 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech customers reined in spending after overspending during the pandemic and China remained "very subdued," the analyst tells investors. Entering 2025, "the setup is almost identical, so there is a healthy dose of skepticism among investors who have been burned over the past year," says the firm, which adds that thinks "there are finally some encouraging signs on the horizon." In conjunction with its year ahead preview for the group, the firm adjusted a number of price targets.

Morgan Stanley

Tejas Savant

Hold

Initiates

$24 → $23

2024-12-03

Reason

Morgan Stanley

Tejas Savant

Price Target

$24 → $23

2024-12-03

Initiates

Hold

Reason

Morgan Stanley analyst Tejas Savant assumed coverage of Stevanato Group with an Equal Weight rating and a price target of $23, down from $24. Stevanato, with "market leading positions" in the biopharmaceutical injectables end market, is well-positioned to benefit in terms of both top-line and margins from a structural mix shift towards biologics and growth in GLP-1s, but vial destocking headwinds, cost under-absorption related to necessary capacity buildouts and optimization expenses are likely to gate estimate upside in the near-term, the analyst tells investors.

Citigroup

Patrick Donnelly

Strong Buy

Maintains

$30 → $28

2024-08-07

Reason

Citigroup

Patrick Donnelly

Price Target

$30 → $28

2024-08-07

Maintains

Strong Buy

Reason

Morgan Stanley

Drew Ranieri

Hold

Maintains

$26 → $22

2024-07-15

Reason

Morgan Stanley

Drew Ranieri

Price Target

$26 → $22

2024-07-15

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Stevanato Group SpA (STVN.N) is 36.38, compared to its 5-year average forward P/E of 38.94. For a more detailed relative valuation and DCF analysis to assess Stevanato Group SpA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

38.94

Current PE

36.38

Overvalued PE

47.50

Undervalued PE

30.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

20.12

Current EV/EBITDA

18.40

Overvalued EV/EBITDA

24.56

Undervalued EV/EBITDA

15.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.20

Current PS

4.39

Overvalued PS

6.23

Undervalued PS

4.17

Financials

Annual

Quarterly

FY2024Q4

YoY :

+3.11%

330.60M

Total Revenue

FY2024Q4

YoY :

+6.18%

70.77M

Operating Profit

FY2024Q4

YoY :

+6.80%

48.31M

Net Income after Tax

FY2024Q4

YoY :

+5.88%

0.18

EPS - Diluted

FY2024Q4

YoY :

-38.19%

-47.55M

Free Cash Flow

FY2024Q4

YoY :

-5.12%

30.75

Gross Profit Margin - %

FY2024Q4

YoY :

-53.93%

-14.29

FCF Margin - %

FY2024Q4

YoY :

+3.54%

14.61

Net Margin - %

FY2024Q4

YoY :

-32.69%

7.31

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.8M

Volume

6-9

Months

0.0

Volume

0-12

Months

1.3M

Volume

Bought

0-3

0.0

Volume

Months

3-6

645.6K

Volume

Months

6-9

0.0

Volume

Months

0-12

1.9M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

STVN News & Events

Events Timeline

2024-11-05 (ET)

2024-11-05

05:41:32

Stevanato Group cuts FY24 adjusted EPS view to UR 0.47-EUR 0.49

2024-11-05

05:39:52

Stevanato Group reports Q3 diluted EPS EUR 0.11 vs. EUR 0.14 last year

2024-10-01 (ET)

2024-10-01

06:34:43

Stevanato to introduce Vertiva 10mL on-body delivery system platform

News

9.5

04-24Newsfilter

Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025

2.0

04-07Benzinga

Tesla, Apple, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

2.0

04-04Benzinga

Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session

People Also Watch

Clearwater Paper Corp

Lithium Americas (Argentina) Corp

Alerus Financial Corp

Montana Technologies Corp

Senseonics Holdings Inc

0.750

USD

+3.88%

FAQ

What is Stevanato Group SpA (STVN) stock price today?

The current price of STVN is 21 USD — it has decreased -2.69 % in the last trading day.

STVN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

STVN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Stevanato Group SpA (STVN) stock price today?

What is Stevanato Group SpA (STVN)'s business?

What is the price predicton of STVN Stock?

What is Stevanato Group SpA (STVN)'s revenue for the last quarter?

What is Stevanato Group SpA (STVN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Stevanato Group SpA (STVN)'s fundamentals?

How many employees does Stevanato Group SpA (STVN). have?

What is Stevanato Group SpA (STVN) market cap?